CPHI Europe

In part 2 of this 2-part interview, Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, tells PharmTech about the challenges in achieving sustainability in pharma and how the CPHI Sustainability Summit, which launches at CPHI Milan 2026, can help organizations tackle these challenges.

PharmTech spoke with Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, about the new Sustainability Summit that will launch at CPHI Milan 2026 and how it can help organizations obtain measurable, commercially viable solutions for sustainability in the pharma industry.

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and the overall experience of attending the CPHI conference.

Frank Romanski of Lonza Capsugel dives into the excipient side of manufacturing and the emerging prevalence of digitalization.

Exclusive interviews revealed that digital transformation, data integrity protocols, and a regionalized supply chain are crucial strategies for optimizing drug development and manufacturing efficiency.

Christian Dowdeswell, managing director, Arcinova, a Quotient Sciences company, discusses what makes a CDMO that offers end-to-end service beneficial.

Maggie Saykali reviews the key points of her CPHI Frankfurt presentation on the potential game-changing opportunities of the Critical Medicines Act.

J.D. Mowery, Bora, says global sustainability standards are good, AI implementation demands data cleansing, and outsourcing must mature.

Patient compliance is driving the emergence of new modalities, as Frank Romanski of Lonza Capsugel explains in the first installment of a two-part discussion.

Sriman Banerjee of Takeda Pharmaceuticals says patient adherence is improving thanks to technologies that offer a more personalized approach.